The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 1, 2010, Pages 92-101

  Allez, M ^a   Vermeire, S ^b   Mozziconacci, N ^c   Michetti, P ^d   Laharie, D ^e   Louis, E ^f   Bigard, M A ^g   HEbuterne X ^h   Treton, X ⁱ   Kohn, A ^j   Marteau, P ^k   Cortot, A ^c   Nichita, C ^d   Van Assche, G ^b   Rutgeerts, P ^b   LEmann M ^a   Colombel, J F ^c  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e HAUT LÉVÊQUE HOSPITAL   (France)

^f UNIVERSITY OF LIÈGE   (Belgium)

^g CHU NANCY BRABOIS   (France)

^h CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

ⁱ BEAUJON HOSPITAL   (France)

^j Polo Ospedaliero USL RMA   (Italy)

^k HÔPITAL LARIBOISIÈRE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; COUGHING; CROHN DISEASE; DEATH; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FEMALE; FOLLOW UP; HEART FAILURE; HERPES ZOSTER; HUMAN; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NONHUMAN; PERIANAL ABSCESS; PRIORITY JOURNAL; PROBABILITY; QUESTIONNAIRE; RETROSPECTIVE STUDY; SEPTIC SHOCK; SIDE EFFECT; SKIN INFLAMMATION; SUDDEN DEATH; TRANSITIONAL BLINDNESS; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 71449114736     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04130.x     Document Type: Article

References (39)

1. Van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut 1997 40 : 443 448.
2. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997 337 : 1029 1035.
3. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002 359 : 1541 1549.
4. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999 340 : 1398 1405. (Pubitemid 29205403)
5. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999 117 : 761 769.
6. Rutgeerts PJ. Review article: efficacy of infliximab in Crohn's disease - induction and maintenance of remission. Aliment Pharmacol Ther 1999 13 (Suppl 4 9 15. discussion 38
7. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004 350 : 876 885.
8. Behm B, Bickston S. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008 : CD006893.
9. Regueiro M, Siemanowski B, Kip KE, Plevy S. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis 2007 13 : 1093 1099.
10. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004 53 : 849 853.
11. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003 348 : 601 608. (Pubitemid 36204954)
12. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003 98 : 1315 1324.
13. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004 2 : 542 553.
14. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003 124 : 917 924.
15. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (ADA) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006 130 : 323 333.
16. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007 56 : 1232 1239. (Pubitemid 47300424)
17. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007 132 : 52 65.
18. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007 357 : 239 250. (Pubitemid 47080388)
19. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007 357 : 228 238.
20. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005 129 : 807 818. (Pubitemid 41242673)
21. Sandborn WJ, Hanauer S, Loftus EV Jr., et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004 99 : 1984 1989.
22. Youdim A, Vasiliauskas EA, Targan SR, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004 10 : 333 338.
23. Papadakis KA, Shaye OA, Vasiliauskas EA, et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005 100 : 75 9.
24. Peyrin-Biroulet L, Laclotte C, Bigard MA. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther 2007 25 : 675 680. (Pubitemid 46272520)
25. Hinojosa J, Gomollon F, Garcia S, et al. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther 2007 25 : 409 418.
26. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007 146 : 829 838.
27. Vermeire S, Abreu MT, D'Hanes G, et al. Efficacy and safety of certolizumab pegol with active Crohn's disease who previously lost response or were intolerant to infliximab: open-label induction preliminary results of the welcome study. Gastroenterology 2008 A 67 : 494.
28. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 Crohn's disease patients: results from a single centre cohort. Gut 2008 58 : 492 500.
29. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980 1 : 514.
30. Nikas SN, Voulgari PV, Alamanos Y, et al. Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Ann Rheum Dis 2006 65 : 257 260.
31. Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006 8 : R29.
32. Solau-Gervais E, Laxenaire N, Cortet B, et al. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatology (Oxford) 2006 45 : 1121 1124.
33. Van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003 62 : 1195 1198.
34. Wick MC, Ernestam S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven RF. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol 2005 34 : 353 358.
35. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007 13 : 1323 1332.
36. Colombel JF, Loftus EV Jr., Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004 126 : 19 31.
37. Sandborn W, Loftus E. Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut 2004 53 : 780 782. (Pubitemid 38662124)
38. Toruner M, Loftus EV Jr., Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008 134 : 929 936.
39. Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-TNFalpha therapy. Results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009 68 : 209 215.